Asset profile
NTRX-07
Small molecule
Evidence outlook · lead readout
NCT06194552 · Alzheimer Disease
The completed lead evidence is positive, with design limits that temper confidence — see the rationale below for exactly which.
NCT06194552: The study randomized participants to placebo or one of several NTRX-07 dose or food conditions under blinded conditions, a controlled design, but results are not yet posted, so treatment-related adverse-event rates cannot be compared between groups.
How the evidence outlook works ↗
Featured trials
Unlock featured-trial analysis
Research includes the instrumental studies, endpoints, key results, design grades, rationales and source links behind the Outlook.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Unlock the complete ClinicalTrials.gov registry
Research includes every linked study, indication filters, phase grouping and featured-trial cross-links.
Competitive landscape
Unlock the competitor landscape
Research compares assets by shared mechanism and indication, including each competitor's stage in the relevant market.